Patents by Inventor Anna Ericsson

Anna Ericsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160311818
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
    Type: Application
    Filed: September 18, 2015
    Publication date: October 27, 2016
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Publication number: 20160311774
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
    Type: Application
    Filed: September 18, 2015
    Publication date: October 27, 2016
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • Publication number: 20160185785
    Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5? and R6 are described herein.
    Type: Application
    Filed: December 29, 2015
    Publication date: June 30, 2016
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, Darby Rye Schmidt, David Joseph Guerin, Justin A. Caravella, R. Bruce Diebold, Anna Ericsson, David Lancia, JR.
  • Publication number: 20160083367
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
    Type: Application
    Filed: September 18, 2015
    Publication date: March 24, 2016
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • Publication number: 20160083365
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.
    Type: Application
    Filed: September 18, 2015
    Publication date: March 24, 2016
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • Publication number: 20160083349
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R8 are described herein.
    Type: Application
    Filed: September 18, 2015
    Publication date: March 24, 2016
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • Publication number: 20160083366
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Application
    Filed: September 18, 2015
    Publication date: March 24, 2016
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • Publication number: 20080076924
    Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
    Type: Application
    Filed: June 29, 2007
    Publication date: March 27, 2008
    Inventors: Patrick Betschmann, William Carroll, Anna Ericsson, Shannon Fix-Stenzel, Michael Friedman, Gavin Hirst, Nathan Josephsohn, Biqin Li, Arturo Perez-Medrano, Michael Morytko, Paul Rafferty, Haipeng Chen
  • Publication number: 20080076767
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: October 5, 2007
    Publication date: March 27, 2008
    Inventors: Yujia Dai, Steven Davidsen, Anna Ericsson, Kresna Hartandi, Zhiqin Ji, Michael Michaelides
  • Publication number: 20070282101
    Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
    Type: Application
    Filed: April 2, 2007
    Publication date: December 6, 2007
    Inventors: Anna Ericsson, Andrew Burchat, Kristine Frank, David Calderwood, Lily Abbott, Maria Argiriadi, David Borhani, Kevin Cusack, Richard Dixon, Thomas Gordon, Kelly Mullen, Robert Talanian, Xiaoyun Wu, Xiaolei Zhang, Lu Wang, Biqin Li, Claude Barberis, Neil Wishart
  • Publication number: 20060074102
    Abstract: A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.
    Type: Application
    Filed: May 13, 2005
    Publication date: April 6, 2006
    Inventors: Kevin Cusack, Jose-Andres Salmeron-Garcia, Thomas Gordon, Claude Barberis, Hamish Allen, Agniezka Bischoff, Anna Ericsson, Michael Friedman, Dawn George, Gregory Roth, Robert Talanian, Christine Thomas, Grier Wallace, Neil Wishart, Zhengtian Yu
  • Publication number: 20060025383
    Abstract: A compound of Formula (I), wherein the substituents are as defined herein, which are useful as kinase inhibitors.
    Type: Application
    Filed: February 3, 2005
    Publication date: February 2, 2006
    Inventors: Neil Wishart, Michael Friedman, Lee Arnold, Bryant Yang, Shannon Fix-Stenzel, Anna Ericsson, Michael Michaelides, Xiao-Dong Qian, James Holms, Douglas Steinman, Zhengping Tian, Steven Wittenberger
  • Publication number: 20060014816
    Abstract: Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: March 24, 2005
    Publication date: January 19, 2006
    Inventors: Lee Arnold, Jurgen Dinges, Richard Dixon, Stevan Djuric, Anna Ericsson, Kimba Fischer, Alan Gasiecki, Vijaya Gracias, James Holms, Makoto Takeshita, Michael Michaelides, Melanie Muckey, Paul Rafferty, Douglas Steinman, Carol Wada, Zhiren Xia, Irini Akritopoulou-Zanze, Henry Zhang
  • Publication number: 20050020603
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: May 10, 2004
    Publication date: January 27, 2005
    Inventors: Yujia Dai, Steven Davidsen, Anna Ericsson, Kresna Hartandi, Zhiqin Ji, Michael Michaelides
  • Patent number: 6825233
    Abstract: There are provided compounds represented by the formula I or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, wherein the various substituents are as defined. Also included are methods for preventing and/or treating tumors, arthritis, and non-malignant skin disorders comprising administering a compound of formula I to a mammal. Further provided are pharmaceutical formulations comprising a compound of formula I in admixture with one or more pharmaceutically acceptable excipients.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: November 30, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anna Ericsson, Anne Marinier, Fred C. Zusi
  • Publication number: 20020193421
    Abstract: There are provided compounds represented by the formula I 1
    Type: Application
    Filed: February 13, 2002
    Publication date: December 19, 2002
    Inventors: Anna Ericsson, Anne Marinier, Fred C. Zusi
  • Patent number: 5945561
    Abstract: Certain novel substituted (5,6)-dihydroanthracenyl compounds of the general formula ##STR1## wherein A, n, p, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are as defined in the specification exhibit retinoid-like properties and are particularly useful in the prevention of post-surgical adhesions.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: August 31, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Starrett, Jr., Kenneth M. Tramposch, Xina Nair, Peter R. Reczek, Anna Ericsson, Anne Marinier, Alain Martel, Fred C. Zusi